The first email in biotech goes to the person who can kill the science.

What you sell changes who can say no

An assay or an instrument is judged by a scientist who has run the comparison. A diagnostic test is judged by the lab lead who would have to change a workflow. A contract research organization or a specialty lab is judged by the sponsor's scientific lead, who already has a way to do the work. Those are three different refusals. Procurement can refuse the order after one of those people has said yes. Procurement cannot supply the yes.

ReplyLead writes to that one person. The client's sellers take the meeting, the scientific argument, and the order. No partner is named, because none is published for this work. Search, ads, design, and a marketing department are not this job.

Who sits down

Two pages already ranking

On 11 October 2026, Google's first results for this query were agencies with a biotech page. Two of those pages were read that day.

Samba Scientific's lead generation page says the work is to reach key decision makers and turn interest into opportunity. The same page lists SEO, ads, and inbound lead generation among its services. That is a marketing menu. It does not name the one person who can reject the science.

Launch Leads' biotech page asks for meetings with qualified research buyers and procurement buyers in the same line. The company it describes has built an assay, an instrument, a reagent line, or a contract research or manufacturing service. Research and procurement are not the same meeting.

ReplyLead publishes this reading of those pages. It is not an independent ranking.

What you pay

A monthly technology fee, plus an agreed share of attributable closed revenue. The fee remains when nothing closes. The tiers sit on the pricing page. The split of the work sits on how it works: ReplyLead builds the outbound engine, and the client closes.

When this does not apply

This page does not apply if you sell to patients, or if the buyer is a hospital or a payer. That work is on healthcare lead generation. It does not apply if you want search, ads, content, or design. It does not apply if you are hiring a general lead generation firm, which is a different page.

ReplyLead has not published a biotech client record. Another industry's count is not evidence for this page, and it is not used here. A booked meeting, a held meeting, an accepted opportunity, and closed revenue are different stages.

How this page was built

The Google results were opened on 11 October 2026. Samba Scientific's lead generation page and Launch Leads' biotech page were read that day. We did not buy or test their services. Facts about them come from those pages. Facts about ReplyLead's commercial terms come from the pricing page and the how-it-works page.

Sources checked 11 October 2026

• How ReplyLead works - ReplyLead builds the outbound engine. The client closes.
• ReplyLead pricing - a monthly technology fee plus a share of attributable closed revenue.
• Healthcare lead generation - hospital and payer work, which this page does not cover.
• Samba Scientific, lead generation - reach key decision makers; SEO, ads, and inbound lead generation are listed on the page.
• Launch Leads, biotech - meetings with qualified research and procurement buyers.

Questions

Who receives the first email?

One person who can reject the science. For an assay or an instrument, that is the scientist. For a diagnostic test, the lab lead. For a contract research organization or a specialty lab, the sponsor's scientific lead. ReplyLead writes to that person by cold email and LinkedIn. The client's team takes the meeting.

Why not procurement?

Procurement can stop an order. Procurement cannot tell you the data are real. ReplyLead does not write to procurement first.

Does ReplyLead run the biotech company's marketing?

No. ReplyLead runs cold email and LinkedIn. Search, ads, content, design, social, and a marketing department are a different scope. No partner is named for that work on this page.

Updated 11 October 2026. Mark Glazer